This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shen, R.-s. Articles by Abell, C. W. Search for Related Content PubMed PubMed Citation Articles by Shen, R.-s. Articles by Abell, C. W.

Clearance of Phenylalanine Ammonia-lyase from Normal and Tumor-bearing Mice¹

Division of Biochemistry, Department of Human Biological Chemistry and Genetics, The University of Texas Medical Branch, Galveston, Texas 77550

Yeast phenylalanine ammonia-lyase was administered i.p. to normal and tumor-bearing mice, and its clearance from plasma was studied. Single and multiple weekly injections at dosages of 10, 20, 50, and 100 units/kg were administered to C57BL female, C57BL x DBA/2 F₁ male, and A/J female mice. L5178Y murine lymphoblastic leukemia, B16 melanoma, BW10232 adenocarcinoma, and 15091A anaplastic carcinoma were implanted 7 to 11 days prior to enzyme injection in the appropriate host. After a single injection, the average plasma half-lives of phenylalanine ammonia-lyase were 18 to 24 hr in all groups studied. While the other tumors had no effect on the plasma level of phenylalanine ammonia-lyase after a single injection, L5178Y murine lymphoblastic leukemia and 15091A anaplastic carcinoma significantly depressed the maximal level of phenylalanine ammonia-lyase attained in the plasma.

After repeated injections of phenylalanine ammonialyase, the initial plasma enzyme level was significantly reduced when 20 units/kg were administered, and the clearance of the enzyme from the plasma was greatly accelerated regardless of the amount administered. Furthermore, in tumor-bearing mice, the rate of clearance was significantly more rapid than in the appropriate non-tumor-bearing control.

¹ This work was supported by USPHS Grant CA-14527 and Contract CB-43906 from the National Cancer Institute.

Received 4/16/76. Accepted 12/28/76.